3SBio of Shenyang rose 5% in its first day of trading in Hong Kong following the company's $711 million IPO; Huaren Pharma, an IV drugmaker, paid $550 million to acquire Hongta Innovation Investment, which holds a 9.2% stake in Huaren; Wandong Medical, a Beijing medical imaging company, raised $147 million from seven investors, including Alibaba's Jack Ma; BioAtla of San Diego and Beijing raised $30 million from an undisclosed group of China investors; The Pharma Partners, a US-China firm, formed a partnership with Suzhou BioBAY and Legend Capital and will raise $30 million to bring four US medical device companies to China; Luqa Pharma announced a $15 million funding led by Morningside Ventures to support its China in-licensing program; Phagelux, a Shanghai anti-bacterial company, reported a $10 million fundraising; Beijing's Annoroad Gene Technology will collaborate with Illumina to develop a next-gen prenatal DNA diagnostic test for China; China is home for three of the top five global entities in terms of biotech patent filings/approvals; and Suzhou NeuPharma began a Australian Phase I clinical trial in patients with solid tumor cancers.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
